While many mechanisms are still to be clarified, compiling potential drugs targeting CTGF provides insights into the development of treatments for pulmonary fibrosis and offers a valuable perspective for future studies on the mechanisms driving the progression of the disease. The gene discussed is CCN2; the disease is pulmonary fibrosis.